In the present study, the researchers sought to explore the connection between immune-related adverse events and recurrence-free survival (RFS) in the double-blind EORTC 1325/KEYNOTE-054 clinical trial comparing pembrolizumab therapy and placebo for the treatment of individuals with high-risk stage III melanoma.
Publications
The prognostic impact of the extent of ulceration in clinical stage I-II melanoma patients: A multicenter study of the Italian Melanoma Intergroup (IMI)
This study was undertaken to determine if the extent of ulceration (EU) predicts relapse free survival (RFS) and overall survival (OS) in primary cutaneous melanoma (PCM).
Trends in malignant melanoma mortality in 31 countries from 1985 to 2015
Using the World Health Organization (WHO) Mortality Database, researchers sought to delineate malignant melanoma (MM) mortality trends between 1985 and 2015.
Risk of melanoma following keratinocyte malignancies
Researchers intended to well-characterize patients at increased risk for melanoma following keratinocyte cancer, using a population-based cohort comprising 2,243 individuals with histologically-verified KC, selected from dermatology and pathology practices, and without a history of internal malignancy (1,363 BCC, 880 SCC).